J.D. Kleinke

J.D. Kleinke Speaking Topics

• What NOW? The US Health Care System after COVID

  First, the good news: after 30 years of hype, hope, and disappointment, telehealth has finally broken through – and all it took was a global pandemic. But thanks to the pandemic, one-third of the medical workforce now wants to quit. How will your organization cope with the coming systemic shock? Will the ongoing migration of medical care to less invasive settings ease some of the burden by re-aligning where patients get their care with where and how your employees would rather work? The question is especially pressing as the demand for all health care services is about to spike, thanks to the “collateral epidemiology” of the pandemic: the medical consequences of patients putting off primary care, cancer screenings, surgeries, and other treatments for two years. Challenges, yes, but they also mean opportunities for organizational transformation in what may be the most significant structural re-alignment of health care in the US since the rise of managed care in the 1990s. This session will outline what both telehealth and traditional medical care will look like in the very near future – and organizational strategies for adapting, surviving, and thriving in the American healthcare system after the pandemic.

Read More +
• Imprecision Medicine

  Will the arrival of artificial intelligence (AI), coupled with the long-awaited emergence of pharmaco-genomics, be the technology that finally breaks managed care’s 40-year business model? As cost-of-production breakthroughs in genomic science finally come to the market, along comes AI, a far cheaper data science with the potential to analyze massive amounts of real-world information on patients. In the next few years and for vastly less computing cost, AI will democratize the same concept behind genomic science: an individual patient is exquisitely clinically unique, and not just genetically – something pricey pharmaco-genomics now reveals – but demographically, custodially, behaviorally. What medical care may work best for an individual patient may have little to do with what an insurer finds may in that patient’s claims history, and everything to do with education, income, racial complexity, neighborhood, domestic stability, food insecurity. Will employer and government purchasers of health care, along with health plans, PBMs, and others operating under the old managed care model, awaken to this new reality, and the opportunity it represents for truly better health care? Or will patients and their well-organized advocates and proxies in Washington and statehouses around the country, have to resort to new legislation to fix what the market cannot?

Read More +
• Health Care Policy & Politics after the Republican Party Populist Makeover

  For decades, health policy and legislation in the US followed a predictable script: one party wanted more regulation of health care providers and payers, more public funding for vulnerable populations, and price controls. The other party preferred to let markets, competition and consumer choice drive the system toward efficiency. The result was a classic political hybrid like the Affordable Care Act, which attempted to split the difference, and a drug industry free to charge what it wanted for its biggest breakthroughs. All of that changed in the last eight years. Now, both parties are calling for price controls on drugs, anti-trust enforcement of health care mergers, and aggressive regulation of billions in private equity acquisitions that were given free reign to roil nearly every kind of health care labor market. While the new partisan math in health policy has turned the once politically unassailable pharmaceutical industry into a political orphan, what other health policy impacts are just around the corner? Might this sudden populist majority, forged across old party lines, drive legislation previously unimaginable? Might it actually be good news for patients, nurses and doctors, difficult news for health insurers, and terrible news for the drug industry?

Read More +
• Once & Future Health Care M&A Strategies: The Best Defense is a Good -- Transaction?

  Health insurers have been reacting to the inflationary spiral and cost compression of the past few years the same way they did to the last assault on their profit margins - managed care in the 1990s - with lockstep acquisitions of each other, of providers, and of businesses with often tenuous relevance to their core competencies. Payers and providers are scrambling to re-align around what many believe will be major changes in reimbursement, health insurance markets, and consumer and patient economic behavior. This session attempts to explain why! We will examine the impact of inflation and intense cost compression on health insurance market upheavals, the collateral impacts on hospitals and physician groups; the emergence of new payment models for astronomically expensive new drugs; and the potential reshuffling of different patient populations in and out of coverage. This speech is not for the faint of heart!

Read More +
• The Patient Is In: New Business Models for Health Care’s Digital Age

  Over the past two decades, the locus of medical decision-making – via the rise and fall of “managed care” – has shifted from physician to health plan to patient. High-deductible health insurance, complex co-payment systems, and the emergence of hundreds of new digital tools for patients are conspiring to change everything we thought we knew about the economic behaviors of healthcare consumers. Payers and providers are scrambling to re-align around these changes, resulting in a series of unusual mergers, acquisitions, and a few wildly new business initiatives and models over the past few years. This session attempts to explain why. We will examine the impact of general inflation, medical cost inflation, and margin compression on health insurance market upheavals, the collateral impacts on hospitals and physician groups, the emergence of new payment models for astronomically expensive new drugs, and the potential reshuffling of different patient populations in and out of coverage. This speech is not for the faint of heart!

Read More +